【参考文献】
  　　[1] Lordkipanidze M,Pharand C, Palisaitis DA, et al. Aspirin resistance:truth or dare[J].Pharmacol Ther，2006,112:733743.

　　[2] Bhatt D, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy[J].Nature Rev，2003,2:1528.

　　[3] WeberA A, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach[J]. Platelets,2002,13:3740.

　　[4] Lee PY, Chen WH, Ng W, et al. Lowdose aspirin increases aspirin resistance in patients with coronary artery disease[J].Am J Med，2005,118:723727.

　　[5] Zczeklik A , Musia J , Undas A , et al. Aspirin resistance [J].J ThrombHaemost，2005,3 : 16551662.

　　[6] Horiuchi H.Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems [J]. Ann Med，2006,38 : 162172.

　　[7] CambriaKiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance [J]. J Thromb Thrombol，2002,13:4956.

　　[8] Ulrich CM, Bigler J, Sibert J, et al. Cyclooxygenase 1 (COX1) polymorphisms in AfricanAmerican and Caucasian populations[J].Hum Mutat，2002,5:409410.

　　[9] Maree AO, Curtin RJ , Chubb A, et al. Cyclooxygenase1 hap lotype modulates platelet response to aspirin[J]. J Thromb Haemost，2005,3: 2 3402 345.

　　[10] GonzalezConejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure [J] . Stroke，2005,36 : 276280.

　　[11] Agnieszka Slowik, Tomasz Dziedzic, et al. A2 alelle of gp3a gene is a risk factor for strok caused by largevessele disease in males[J]. Stroke，2004,35:1 5891 593.

　　[12] Grove EL , Orntoft TF ,Lassen JF , et al . The platelet polymorphism PLA2 is a genetic risk factor for myocardial infarction [J] . J Intern Med，2004 ,255 :637644.

　　[13] Papp E, Havasi V, Bene J, et al. Glycoprotein 3A gene (PlA) polymorphism and aspirin resistance: is there any correlation[J].Ann Pharmacother，2005,39:1 0131 018.

　　[14] Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP 3a) polymorphism but not with C807T (GP 1a/4a) and C5T Kozak (GP 1ba) polymorphisms[J].J Am Coll Cardiol，2003,42:1 1151 119.

　　[15] Kunicki TJ, Orchekowski R, Annis D，et al. Variability of integrin α2β1 activity on human platelets[J].Blood,1993,82: 2 6932 703.

　　[16] Andre P, LaRocca T, Delaney SM, et al. Anticoagulants ( thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis [J].Circulation，2003,108: 2 6972 703.

　　[17] Steinhubl SR, Berger PB, Mann JT , et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial[J]. JAMA，2002,288: 2 4112 420.

　　[18] Fontana P,DupontA, Gandrille S, et al. Adenosine diphosphateinduced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects[J].Circulation，2003,108: 989995.

　　[19] Jefferson BK, Foster JH,McCarthy JJ , et al. Aspirin resistance and a single gene[J]. Am J Cardiol，2005,95: 805808.